InvestorsHub Logo
icon url

IgnoranceIsBliss

03/09/23 8:03 AM

#405344 RE: Nukemtiltheyglow #405264

If you remove the patent woes for Vascepa, I'd MORE than agree with you.

The runway on the MDCO drug is clearer and longer. That has a huge impact on its value to an acquirer.